Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

D. James, Nicholas; Spears, Melissa; W. Clarke, Noel; P. Dearnaley, David; S. de Bono, Johann; Gale, Joanna; Hetherington, John; Hoskin, Peter; J. Jones, Robert; Laing, Robert; Lester, J.F.; B. McLaren, Duncan; Parker, Christopher; Parmar, Mahesh; Ritchie, A.W.S.; M. Russell, John; T. Strebel, Räto; N. Thalmann, George; D. Mason, Malcolm; R. Sydes, Matthew

doi:10.1016/j.eururo.2014.09.032

Public

Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

Published in European Urology • Oct 7, 2014

Authors:

Nicholas D. James

Melissa Spears

Noel W. Clarke

Abstract

BACKGROUND: Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa--the Systemic Therapy in Advancing or Metastatic Pros...

Subject

Medicine

Interquartile range

Prostate cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!